分泌型卷曲相关蛋白2(SFRP2)表达通过经典WNT信号通路促进病灶增殖并指示卵巢外子宫内膜异位症病灶边界
研究分析47名健康对照和103名子宫内膜异位症患者的子宫内膜(n=104)与子宫内膜异位症标本(n=177),发现SFRP2与CTNNB1在卵巢外子宫内膜异位症中差异表达,可作为病灶边界标志物,SFRP2表达与疼痛症状正相关,功能缺失降低原代细胞增殖。
要点
- SFRP2与CTNNB1在卵巢外子宫内膜异位症中差异表达,可辅助CD10识别病灶边界。
- SFRP2表达与患者疼痛症状正相关(P<0.05)。
- SFRP2功能缺失使原代细胞增殖下降(P<0.05),伴CTNNB1蛋白降低(P=0.05)。
核心结论
- SFRP2在子宫内膜异位症中作为经典WNT/CTNNB1信号激动剂,调控病灶生长并与CTNNB1共同指示病灶边界。
研究设计与样本
- 基于腹腔镜或刮宫收集的临床样本队列及健康对照和子宫内膜异位症患者问卷数据,纳入47名健康对照和103名子宫内膜异位症患者,分析子宫内膜(n=104)和子宫内膜异位症(n=177)标本。
- 采用全局基因表达分析、生物信息学和qPCR分析,并以免疫组化、Western blotting、原代细胞培养和siRNA敲低验证。
主要发现
- 分析的220个WNT信号和CTNNB1靶基因中,184个基因在卵巢外子宫内膜异位症中较子宫内膜组织差异表达(P<0.05),包括SFRP2和CTNNB1。
- 子宫内膜中观察到的WNT基因月经周期依赖性调控在子宫内膜异位症病灶中丧失,如层次聚类所示。
- 免疫组化显示SFRP2和CTNNB1是新的子宫内膜异位症病灶边界标志物,补充已知标志物CD10的免疫染色。
- SFRP2和CTNNB1在卵巢外子宫内膜异位症组织的上皮和间质中定位相似,且均指示额外的远处病灶边界,提示子宫内膜异位症间质中WNT信号在CD10指示的原发边界之外发生改变。
- SFRP2表达与患者疼痛症状正相关(P<0.05);卵巢外子宫内膜异位症原代细胞培养中SFRP2功能缺失导致细胞增殖下降(P<0.05),伴CTNNB1蛋白表达降低(P=0.05)。
临床怎么用
- 高表达的SFRP2和CTNNB1改善子宫内膜异位症病灶边界检测,可能对优于CD10的病灶可视化有临床意义。
- SFRP2在子宫内膜异位症中作为经典WNT/CTNNB1信号激动剂并正向调控病灶生长,提示WNT通路可能是子宫内膜异位症的重要治疗靶点。
局限性
- SFRP2和CTNNB1在相对较小的队列(n=20)中改善了卵巢外子宫内膜异位症病灶边界检测。
- 需要更大规模的研究,涵盖不同月经周期阶段和激素用药下的不同子宫内膜异位症亚型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the role of SFRP2 in endometriosis? SUMMARY ANSWER: SFRP2 acts as a canonical WNT/CTNNB1 signaling agonist in endometriosis, regulating endometriosis lesion growth and indicating endometriosis lesion borders together with CTNNB1 (also known as beta catenin). WHAT IS KNOWN ALREADY: Endometriosis is a common, chronic disease that affects women of reproductive age, causing pain and infertility, and has significant economic impact on national health systems. Despite extensive research, the pathogenesis of endometriosis is poorly understood, and targeted medical treatments are lacking. WNT signaling is dysregulated in various human diseases, but its role in extraovarian endometriosis has not been fully elucidated. STUDY DESIGN, SIZE, DURATION: We evaluated the significance of WNT signaling, and especially secreted frizzled-related protein 2 (SFRP2), in extraovarian endometriosis, including peritoneal and deep lesions. The study design was based on a cohort of clinical samples collected by laparoscopy or curettage and questionnaire data from healthy controls and endometriosis patients. PARTICIPANTS/MATERIALS, SETTING, METHODS: Global gene expression analysis in human endometrium (n = 104) and endometriosis (n = 177) specimens from 47 healthy controls and 103 endometriosis patients was followed by bioinformatics and supportive qPCR analyses. Immunohistochemistry, Western blotting, primary cell culture and siRNA knockdown approaches were used to validate the findings. MAIN RESULTS AND THE ROLE OF CHANCE: Among the 220 WNT signaling and CTNNB1 target genes analysed, 184 genes showed differential expression in extraovarian endometriosis (P < 0.05) compared with endometrium tissue, including SFRP2 and CTNNB1. Menstrual cycle-dependent regulation of WNT genes observed in the endometrium was lost in endometriosis lesions, as shown by hierarchical clustering. Immunohistochemical analysis indicated that SFRP2 and CTNNB1 are novel endometriosis lesion border markers, complementing immunostaining for the known marker CD10 (also known as MME). SFRP2 and CTNNB1 localized similarly in both the epithelium and stroma of extraovarian endometriosis tissue, and interestingly, both also indicated an additional distant lesion border, suggesting that WNT signaling is altered in the endometriosis stroma beyond the primary border indicated by the known marker CD10. SFRP2 expression was positively associated with pain symptoms experienced by patients (P < 0.05), and functional loss of SFRP2 in extraovarian endometriosis primary cell cultures resulted in decreased cell proliferation (P < 0.05) associated with reduced CTNNB1 protein expression (P = 0.05). LIMITATIONS REASONS FOR CAUTION: SFRP2 and CTNNB1 improved extraovarian endometriosis lesion border detection in a relatively small cohort (n = 20), although larger studies with different endometriosis subtypes in variable cycle phases and under hormonal medication are required. WIDER IMPLICATIONS OF THE FINDINGS: The highly expressed SFRP2 and CTNNB1 improve endometriosis lesion border detection, which can have clinical implications for better visualization of endometriosis lesions over CD10. Furthermore, SFRP2 acts as a canonical WNT/CTNNB1 signaling agonist in endometriosis and positively regulates endometriosis lesion growth, suggesting that the WNT pathway may be an important therapeutic target for endometriosis. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the Academy of Finland and by Tekes: Finnish Funding Agency for Innovation. The authors have no conflict of interest to declare.
引用
- Heinosalo T, Gabriel M, Kallio L, et al. Secreted frizzled-related protein 2 (SFRP2) expression promotes lesion proliferation via canonical WNT signaling and indicates lesion borders in extraovarian endometriosis. Hum Reprod. 2018. PMID: 29462326. doi:10.1093/humrep/dey026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。